Company profile
Cypralis | Novel Medicines for Acute and Chronic Degenerative Diseases
Cypralis Limited is a UK company with status active founded in 2012 based in East of England.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNTM3OTc3MmFkaXF6a2N4
Published 12 Sep 2024 08:43
AD02 | Transaction MzQzMTk5NTkyMWFkaXF6a2N4
Published 13 Aug 2024 14:34
CS01 | Transaction MzQzMTk4MzQ2NGFkaXF6a2N4
Published 13 Aug 2024 12:32
Company registered at Companies House
1 Aug 2017 to 31 Jul 2018
Chronic pancreatitis is a severely painful inflammation of the pancreas that frequently requires admission to hospital and prevents normal life. Currently there is no drug treatment that affects the course of chronic pancreatitis and patients are typically treated only to alleviate their pain. As the disease progresses the pancreas undergoes degradation, ...
1 Jan 2017 to 31 Dec 2017
The current project is directed at the development of a new therapy to treat acute pancreatitis (AP). AP is an extremely painful disease that is most often associated with gall stones, excessive alcohol intake and obesity and is currently treated in the hospital with supportive therapy only. However, a significant proportion of patients with AP can progre...
1 Oct 2015 to 31 Oct 2016
The project will identify novel, selective inhibitors of cyclophilin D which is an attractive target for the treatment of acute pancreatitis, an orphan disease with no available drug therapies. Cyclosporin, a marketed drug which is known to inhibit cyclophilin D, cannot be used for treating acute pancreatitis because of its other properties including immu...
